{
    "root": "2f876ad0-fc53-b260-e063-6394a90a1e60",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Metoprolol Tartrate",
    "value": "20250304",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "D&C RED NO. 30",
            "code": "2S42T2808B"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "METOPROLOL TARTRATE",
            "code": "W5S57Y3A5L"
        }
    ],
    "indications": "Hypertension\n                  \n                  Metoprolol tartrate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents.\n                  \n                     Angina Pectoris\n                  \n                  Metoprolol tartrate tablets are indicated in the long-term treatment of angina pectoris.\n                  \n                     Myocardial Infarction\n                  \n                  Metoprolol tartrate tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol. Oral Metoprolol tartrate tablets therapy can be initiated after intravenous metoprolol therapy or, alternatively, oral treatment can begin within 3 to 10 days of the acute event. (See\n \n  DOSAGE AND ADMINISTRATION, \n \n  CONTRAINDICATIONS, and\n \n  WARNINGS).",
    "contraindications": null,
    "warningsAndPrecautions": "Metoprolol Tartrate Tablets, USP are available containing 25 mg of metoprolol tartrate, USP.\n                  The 25 mg tablets are film-coated, pink colored, round, biconvex tablets debossed with R 25 on one side and scored on the other side.\n                  \n                  NDC: 70518-2024-00\n                  NDC: 70518-2024-01\n                  NDC: 70518-2024-02\n                  NDC: 70518-2024-03\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 60 in 1 BOTTLE PLASTIC\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 180 in 1 BOTTLE PLASTIC\n                  \n                  Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]\n                  Protect from moisture.\n                  \n                  Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Hypertension and Angina\n                  \n                  Metoprolol tartrate tablets are contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see\n \n  WARNINGS).\n\n \n                  Hypersensitivity to metoprolol and related derivatives, or to any of the excipients; hypersensitivity to other beta-blockers (cross-sensitivity between beta-blockers can occur). \n  \n                       Sick-sinus syndrome. \n    Severe peripheral arterial circulatory disorders.\n \n                  \n                     Myocardial Infarction\n                  \n                  Metoprolol is contraindicated in patients with a heart rate < 45 beats/min; second- and third-degree heart block; significant first-degree heart block (P-R interval ≥ 0.24 sec); systolic blood pressure < 100 mmHg; or moderate to severe cardiac failure (see\n \n  WARNINGS)."
}